Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma

NCT03309111 is registered in ClinicalTrials.gov with Ichnos Sciences SA as lead sponsor.

NCT NCT03309111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03309111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma
Lead sponsor
Ichnos Sciences SA
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2017
Completion date
December 15, 2023
Enrollment
81 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma